

Supplementary Table 1: Summary of studies examining β 2 microglobulin and survival in patients with renal cell carcinoma

Variables	Palmateer et al., 2025	Lucarelli et al., 2014	Rasmuson et al., 1995
Population	American with local and metastatic RCC	Italian with local and metastatic RCC	Swedish with local and metastatic RCC
Patient number	429	332	145
β 2 microglobulin threshold	≥ 2.34 mg/L	> 2.6 mg/L	≥ 3.0 mg/L
Exclusionary criteria	eGFR < 15 mL/min/1.73m ²	eGFR < 60 mL/min/1.73m ²	Cr < 125 μ mol/L
Metastatic disease*	162 (37.6)	27 (8.1)	56 (38.6)
Nuclear grade 3-4*	314 (80.3)	120 (36.2)	107 (73.8)
pT1-T2	163 (38)	254 (76.2)	NA
Median tumor size	7.5 cm	4.5 cm	NA
Kaplan Meier	OS: p < 0.0001 CSS: p = 0.0005	CSS: p = 0.001 PFS: 0.06	OS: p = 0.001
MVA	OS: HR 1.58, p = 0.035 CSS: HR 2.08, p = 0.009	CSS: p = 0.97 PFS: p = 0.51	OS: HR 1.26, p = 0.39

*reported as n(%). Statistically significant parametric p-values (< 0.05) are bolded. Abbreviations: renal cell carcinoma (RCC), estimated glomerular filtration rate (eGFR), overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS)